Colossal Biosciences Acquires Pet‑Cloning Firm Viagen

Why It Matters

The acquisition underscores the commercial expansion of cloning technology, potentially lowering costs and accelerating its application in both pet markets and wildlife conservation. Successful clones of endangered species could bolster genetic diversity, but the practice also raises ethical debates about resource allocation and the limits of biotechnology in preserving biodiversity.

Deal Summary

Colossal Biosciences announced this week that it has acquired Viagen, a leading pet‑cloning company known for high‑profile projects. Viagen will continue operating under its current leadership, and the terms of the deal were not disclosed.